Phase II study of chemotherapy with UFT/LV/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer.

ABSTRACT: Interventions: UFT 300mg/m2/day and LV 50mg/body/day is administered orally for 21 days every 28 days. Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2618906 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR